Director's Message


The University of Toronto McLaughlin Centre’s sphere of impact continues to grow. We’ve funded DNA research that miraculously allows children to overcome a disabling movement disorder and walk for the first time. We’ve funded genomic research to map factors underlying brain cancer, enabling rational treatment options. We’ve funded futuristic genome sequencing to facilitate earlier and more accurate diagnosis of autism. We’ve also supported research on ethics, policy and education for the Canadian Personal Genome Project -- a McLaughlin Centre-led initiative to illuminate the path for 21st century medical practice. Our funding formula will continue to support excellence in genomics research and education close to the patient, in partnership with anyone who shares our vision. I welcome you to join us.

STEPHEN SCHERER, PhD DSc FRSC, Director, McLaughlin Centre


Education Program Director’s Message


Genomic medicine is experiencing a revolutionary period, reflected by discoveries enhancing the basic understanding of genomic organization, gene expression, epigenetics and genome variation. The dividends for human health are potentially staggering. The physician scientist occupies a critical niche where genomics research intersects medical science and practice. To move medicine forward, our trainees will need to understand the challenges most relevant to patients and, more broadly, to the healthcare system. They will need to integrate this new found knowledge of genomics with their own research questions informed by the patients they see, so this is where the McLaughlin Centre is making strategic investments.

NORMAN ROSENBLUM, MD FRCPC, Education Program Director, McLaughlin Centre

Visit MD/PhD Program
Visit CREMS Programs


Chair of Oversight Committee’s Message


In 40 years as a clinician-scientist at the University of Toronto, I have had a terrific opportunity to witness first-hand the impact of McLaughlin philanthropy. It began with travelling fellowships, and continues through the Centre’s concentration on genomics research and genomic medicine, with ongoing contribution to medical education through the MD/PhD program, directed so ably by Dr. Norman Rosenblum. I have been thrilled to witness the Centre’s magical transformation under Director Steve Scherer. The university hospitals participate in its matching concept, and the focus on early-stage projects supports those that might otherwise never get started. Major gains by McLaughlin-funded scientists are advancing our ability to diagnose and treat numerous conditions with a genomic basis, including autism, certain forms of epilepsy, and specific brain tumours. The University can take great pride in work of the Centre’s director and staff, and by other scientists who have distinguished themselves locally and internationally through McLaughlin funds.

CHARLES TATOR, CM MD PhD FRCSC FACS, Chair Oversight Committee
Director, McLaughlin Centre